Investigating Denosumab as an add-on neoadjuvant treatment for RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-Paclitaxel schedules – 2 × 2 factorial design (GeparX) - Kümmel, S; Minckwitz, G von; Vladimirova, V; Nekljudova, V; Wimberger, P; Denkert, C; Just, M; Hanusch, C; Stötzer, O; Huober, J; Hofmann, M; Jackisch, C; Blohmer, JU; Schneeweiss, A; Untch, M; Loibl, S (Senologie - Zeitschrift für Mammadiagnostik und -therapie, 2018)